Recruiting

Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab

The main goal of this study is to test a virtual reality (VR) program, Survivors' Virtual Reality Survivorship Experience (SurviVRSE), designed to help Breast Cancer survivors (n=30) learn about heart health. The aims are to test the usability, feasibility, and acceptability o the intervention. Additionally, follow-up assessments will examine changes in women's cancer therapy related cardiac dysfunction knowledge and heart healthy behaviors (e.g., physical activity).

ClinicalTrials.gov IDNCT07426913

PhaseNA

Enrollment30

SponsorVirginia Commonwealth University

Age18 Years

SexFEMALE

I'm interested View official listing

Conditions studied

Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer, Virtual Reality, Trastuzumab

About this study

Interventions

Behavioral: Cardiovascular Health Education and Gaming through Virtual Reality — Prior to engaging the intervention, participants will complete a baseline survey. The virtual reality intervention will be delivered at one infusion treatment. Participants will complete all education modules and affiliated games. The education focuses on potentially cardiotoxic treatments (e.g., anthracyclines), ways to identify cancer treatment related cardiovascular dysfunction, and heart healthy behaviors that survivors can initiate during survivorship. Following the intervention participants will complete a survey similar to the baseline survey. One-month following the intervention participants will complete one final survey.

Primary outcomes

CTRCD Knowledge (Baseline, within 2 days post-Intervention, and 4 weeks post-intervention)
Usability (Within 2 days post-Intervention)
Acceptability (Within 2 days post-Intervention)
User Satisfaction (Within 2 days post-Intervention)

Eligibility information

Inclusion Criteria: * 18 years of age or older * Able to speak and read in English * Actively receiving Trastuzumab or an anthracycline-based treatment * Currently receiving immunotherapy. This includes pembrolizumab and atezolizumab. * Diagnosed with stages 0-III Breast Cancer Exclusion Criteria: \- History of prior Breast Cancer diagnosis (i.e., not their first breast cancer diagnosis)

Study locations

Adult Outpatient Pavilion, Richmond, Virginia 23220 United States
Cellular Immunotherapies and Transplant Department, Richmond, Virginia 23220 United States
VCU Health at Stony Point, Richmond, Virginia 23223 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.